Login to Your Account



XBiotech's 'True Human' Antibody Xilonix Hits the Spot for Cachexia

By Anette Breindl
Science Editor

Friday, October 5, 2012

Austin-based XBiotech Inc. is launching its first Phase III trial, for its antibody Xilonix (MABp1), after announcing Wednesday that the monoclonal antibody received fast-track designation by the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription